and Jason, everyone. you, good morning, Thank
I with Phase topoisomerase-X expansion our initial collaborators. accomplished or advanced topo-X data, Fast several granted supporting the inhibitor, designation for Track ADC, the Immunosynthen escalation a previously time, ADC growing portion have great positive deal our we of Mersana, lead we the a Over additional also has been ADC. breast cancer with portion of Dolasynthen population I we most treated Phase trial notably while and that same XMT-XXXX, At dose reported lead months, at here the with past started our an our Emi-Le, a clinical were
XXXX enrolled targeting clinical who from data XXX and January, reported XX, and as AST, generally were the differentiated in and asymptomatic data focus The we are fatigue. nausea adverse treatment-related on escalation proteinuria, In cutoff. generally was From Let's any safety tolerability BX-HX. of dose grade highly standpoint, cohorts a December Emi-Le, backfill ADC be reversible to of transient ADC patients low-grade events Emi-Le first Mersana's in within space. low-grade observed increases initial common most and
did Importantly, to platinum lung unlike monotherapy with neuropathy, other disease have it and that as combinations the an importantly, ADCs, with confidence dose-limiting like many provides neutropenia, ADCs chemotherapy care Emi-Le other that our ocular also not we profile could This toxicity, attractive be see or we challenged could competitors standards us thrombocytopenia. just interstitial would of believe enable pursue.
These XX per rate confirmed patients endometrial cystic confirmed clinical kilogram, from cancer responses types XX% all hormone included a receptor meter were response and observed as doses, range which tumor XX% milligrams define known enrolled an about across objective positive negative activity with milligrams to breast objective intermediate triple about squared ACC-X. otherwise IHC as X type tumor expression, the X, per and score to high From with standpoint, in cancer, carcinoma or At more. adenoid BX-HX types. X XX all we or ovarian of was cancer, which
for a a we are who with least believe BX-HX for We high been key have high with negative At portion few TNBC confirmed the Focusing at one of XX%. was a reasons. ADC, with patients specifically previously ORR triple XXXX, expansion very also initiated trial of in need. range treated in end this topo-X with cancer, unmet patients on positioned breast evaluable we dose our the population the success the
is first we're dose the utilizing. The
inclusion second criteria. The is our
And these the for the is patients competitive in today. standard of final care environment the factor operating. which we is Third are
to that increase might Emi-Le's activity we tends expect, Generally clinical seen Let's the dose. dose. begin you with with speaking, along as have
to XX observed of doses squared. As from we a across per generated I ORR XX was mentioned, the about range meter XX% milligrams
dose this top every the milligrams from X expansion. specifically brought meter range, XX.X weeks have per into squared We
particular we this tolerated. previously dose reported, well was As
dose XX reductions data received the as high who patients or target achieved of durations Additionally, lesion approximately weeks of BX-HX and cutoff. each more on each X the of this treatment also for remained
well-established response A breast influence second in is factor prior can treatment. that and This oncology in is cancer. specifically triple-negative
topo-X As that than the these of therapy, favorably TNBC X and XX data to ORR prior in of evaluable XX% historical lines ADC. patients, was XX received a all Emi-Le received with compare least we had a more generated reminder, at observed of and population benchmarks. one These patients
XX% ASCENT in also X therapy prior with seen But in than topo Phase who more course, a was was in instance, ORR of naive For a III study. the received of setting. lines Trodelvy TNBC this patients
mind only in to X%. care Trodelvy's that must at standard expansion, least single of X received therapy. of lines enrollment X in or In the a important to In of prior arm with XX% a also ORR mandating ADC. today. is increased TNBC of in while chemo, what lines have nearly control which prior been are was topo-X maximum who about we patients patients is also X limiting treatment prior only ORR agent to ASCENT, an the keep had It one
as the our is for notably, within the Pfizer, have be recently finally, ADC we space, primary there announced cancer candidate. that BX-HX that We of its had And breast as would within viewed competitor developments view the environment. Emi-Le. discontinued competitive development BX-HX landscape company it recent favorable the ADC Most
all similar of us payloads. The at other are as that ADCs stage development a clinical have topo-X BX-HX
result, believe unlike we resistance a Emi-Le, are subject they to topo-X As mechanisms.
significant prior who trials. positions advanced auristatin to the clinical which most as appear of a Emi-Le In This ADC class, be fact, the in opportunity us provides their with patients some received these from excluding breast cancer. topo-X therapies have in companies
while we indications given the across as are we is activity we and by level clinical with our excited immediate Emi-Le's potential other in tumor And types, seen We interest focus, TNBC well. pleased of engagement are the have seeing. all investigator are
milligrams squared. continues of per expansion enrollment meter And so at our dose XX.X initial
up officially trial clinical investigate to per to milligrams at related escalation protocol doses report the January we're in were squared continue that to late backfill our seek XX of delays, in seeing cohorts doses. high amended mitigate meter that as proteinuria dose also we pleased to We we we
We for cohort plan second additional present identify this as of our second expect efforts TNBC a us to we well. these post from dose escalation this dose expansion year and will topo-X in backfill later help later year, data
Moving other on to areas.
trial targeting portion escalation have HERX. our data advanced candidate's ability this XXXX in we of dose selectively in trial our to clinical ADC Phase also novel epitope recent is We from in characterize the plan activate XMT-XXXX Later that or XXXX, agonist clinical helps initial I to present a STING to pathway the pharmacodynamic STING Immunosynthen months. of tumors. this HERX-expressing
KGaA. I research and that we Merck to collaboration finally, with make our would research And continue solid with to J&J, our Immunosynthen like progress note in collaboration Dolasynthen
to With color turn things on some let's that, Brian over for our financials.
